HeartMate III is a next-generation continuous flow left ventricular assist device (:LVAD) based on fully magnetically levitated technology. This technology helps in reducing adverse event rates ...
PLEASANTON, Calif., /PRNewswire/ -- Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that its CE ...
Abbott is recalling a system monitor used with the Heartmate cardiac pump because screen display issues could pose a risk to patients. The Class 1 recall affects 4,842 monitors distributed in the U.S.
November 17, 2009 (Orlando, Florida) — Advanced heart-failure transplant-ineligible patients with Thoratec's HeartMate II continuous-flow left-ventricular assist device (LVAD) have better-than-even ...
ST. PAUL, Minn.-- (BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the company has received an Innovation Award for its HeartMate 3 ™ Left ...
Cleveland, OH - Patients implanted with a HeartMate II (Thoratec) left ventricular assist device (LVAD) following its 2008 FDA approval have had similar outcomes to what was predicted by the ...
PLEASANTON, Calif., Thoratec Corporation, a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced the first ever HeartMate 3™ implant ...
MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...
Thoratec Corp. on Wednesday won U.S. approval to sell an implantable heart device as a permanent treatment for patients too sick for transplants, opening a new market for the product. Thoratec already ...
New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for ...
Abbott Laboratories' HeartMate 3 heart pump for advanced heart failure kept more patients alive for two years with fewer incidents of stroke than the company's prior left ventricular assist device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results